press release

May 5, 2017

- Sanofi Genzyme Elects not to Opt in for ALN AS1 in Acute Hepatic Porphyrias Alnylam Intends to Commercialize ALN AS1 Globally upon Product Approval CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company today announced that, pursuant to the companies' global alliance signed in January 2014, Sanofi Genzyme elected ...

press release

May 5, 2017

Interim Results from ORION 1 Phase 2 Study of Inclisiran to be Presented in Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions on November 15, 2016 CAMBRIDGE, Mass. & PARSIPANY, N.J. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a leading biopharmaceutical development ...

press release

May 5, 2017

- In First Cohort (N=4) of Porphyria Patients with Recurrent Attacks, Givosiran Achieves a 74% Mean Decrease in Annualized Attack Rate Company to Meet with Regulatory Authorities for Potential Phase 3 Start in Late 2017 Management to Discuss New Clinical Data in Webcast Conference Call Tomorrow, Sunday, December 4 at 1:00 p.m. ET CAMBRIDGE, Mass. (BUSINESS WIRE) ...

press release

May 5, 2017

- Once Monthly, Subcutaneous Fitusiran Achieves Median Annualized Bleeding Rate (ABR) of 1.0, with Median Observation Period of 5.7 Months Fitusiran Generally Well Tolerated with No Thromboembolic Events Alnylam On Track to Initiate Phase 3 Program in Early 2017 Management to Discuss New Clinical Data in Webcast Conference Call Today, Sunday, December 4, at 1:00 p.m. ET CAMBRIDGE, ...

press release

May 5, 2017

- Advanced RNAi Therapeutics Pipeline with Eight Active Clinical Programs and Multiple Clinical Data Presentations Discontinued Revusiran Development, Focusing on Patisiran and ESC GalNAc Conjugate Programs Company Announces Initiation of Expanded Access Program with Patisiran for Patients with Hereditary ATTR Amyloidosis with Polyneuropathy Maintained Strong Balance Sheet with $1.19 Billion in Cash and Remains On Track to End ...

press release

May 5, 2017

CAMBRIDGE, Mass. & MAIDENHEAD, United Kingdom (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced the expansion of its global footprint with the opening of a new development and commercial hub in Maidenhead, UK. In anticipation of substantial growth across Alnylam over the next five years, the office opens with ...

press release

May 5, 2017

  Clinical Data from Phase 1/2 Study of ALN AAT, an Investigational RNAi Therapeutic Targeting Alpha 1 Antitrypsin (AAT) for the Treatment of AAT Deficiency Associated Liver Disease, Demonstrate Dose Dependent and Durable AAT Knockdown Company to Pursue Follow On Candidate with Improved Tolerability Profile; Expects to File Clinical Trial Application in 2017 In Addition, Alnylam Presents Non Clinical Data ...

press release

May 5, 2017

- Expected Top line Data Readout Remains Unchanged in Mid 2017 CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that the Data Monitoring Committee (DMC) for the Phase 3 APOLLO study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy (hATTR PN) met on October 7, 2016 ...

press release

May 5, 2017

- ALN GO1 Achieves Human Proof of Concept with Statistically Significant Increases in Glycolate, a Biomarker of Effective Glycolate Oxidase Knockdown, in Healthy Adult Volunteers Single Doses of ALN GO1 Found to be Generally Well Tolerated Company to Discuss Clinical Data during ALN GO1 RNAi Roundtable on Tuesday, September 27 at 10:00 a.m. ET CAMBRIDGE, Mass. (BUSINESS WIRE) ...

press release

May 5, 2017

- Advanced Two Programs into Phase 1 Clinical Studies: ALN TTRsc02 for Transthyretin Mediated Amyloidosis and ALN HBV for Chronic Hepatitis B Virus Infection Presented Clinical Data from Patisiran, Revusiran, Fitusiran, and ALN CC5 Programs Maintained Strong Balance Sheet with $1.28 Billion in Cash and Remains On Track to End 2016 with Greater than $1.0 Billion in Cash CAMBRIDGE, Mass. (BUSINESS ...